$HSTC
HST Global Inc

2024 Q2 Form 10-K Financial Statement

#000167479624000003 Filed on April 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.56K $35.47K $140.9K
YoY Change -49.8% 2.54% -0.09%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $16.56K $35.47K $140.9K
YoY Change -49.82% 2.54% -0.09%
Operating Profit -$16.56K -$140.9K
YoY Change -49.82% -0.09%
Interest Expense $84.00 -$1.430K -$5.300K
YoY Change -93.56% 27.68% -231.22%
% of Operating Profit
Other Income/Expense, Net -$84.00 -$5.303K
YoY Change -93.56% 31.29%
Pretax Income -$16.64K -$36.90K -$146.2K
YoY Change -51.48% 3.33% 0.79%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$16.64K -$36.90K -$146.2K
YoY Change -51.48% 3.33% 0.78%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 -$0.03
Diluted Earnings Per Share $0.00 -$0.01 -$0.03
COMMON SHARES
Basic Shares Outstanding 5.249M shares 5.249M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.160K $1.530K $1.530K
YoY Change 122.41% 705.26% 705.26%
Cash & Equivalents $5.155K $1.530K $1.530K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.155K $1.530K $1.530K
YoY Change 122.2% 705.26% 705.26%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.155K $1.530K $1.530K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $5.155K $1.530K $1.530K
YoY Change 122.2% 705.26% 705.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.350K $2.280K $2.280K
YoY Change -99.68% -99.37% -99.37%
Accrued Expenses $80.00 $493.0K $493.0K
YoY Change -99.22% 6302.6% 6302.6%
Deferred Revenue
YoY Change
Short-Term Debt $21.60K $98.32K $98.32K
YoY Change -75.8% 29.23% 29.23%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.03K $593.6K $593.6K
YoY Change -95.59% 33.08% 33.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $23.03K $593.6K $593.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $23.03K $593.6K $593.6K
YoY Change -95.59% 33.08% 33.08%
SHAREHOLDERS EQUITY
Retained Earnings -$6.065M -$6.015M
YoY Change 2.08% 2.49%
Common Stock $41.56K $5.248K
YoY Change 691.92% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$17.88K -$592.1K -$592.1K
YoY Change
Total Liabilities & Shareholders Equity $5.155K $1.530K $1.530K
YoY Change 122.2% 705.26% 705.26%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$16.64K -$36.90K -$146.2K
YoY Change -51.48% 3.33% 0.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $18.52K -$5.480K -$20.91K
YoY Change -721.48% 19.39% -0.59%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -14.20K 5.000K 22.24K
YoY Change -373.6% 11.11% 5.9%
NET CHANGE
Cash From Operating Activities 18.52K -5.480K -20.91K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities -14.20K 5.000K 22.24K
Net Change In Cash 4.320K -480.0 1.330K
YoY Change 95.48% 433.33% -3900.0%
FREE CASH FLOW
Cash From Operating Activities $18.52K -$5.480K -$20.91K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Entity File Number
EntityFileNumber
000-15303
CY2023 dei Entity Registrant Name
EntityRegistrantName
HST GLOBAL, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
73-1215433
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
150 Research Drive
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Hampton
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
23666
CY2023 dei City Area Code
CityAreaCode
757
CY2023 dei Local Phone Number
LocalPhoneNumber
766-6100
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q2 dei Entity Public Float
EntityPublicFloat
96779 usd
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5248582 shares
CY2023 dei Auditor Firm
AuditorFirmId
76
CY2023 dei Auditor Name
AuditorName
Turner, Stone & Company, LLP
CY2023 dei Auditor Location
AuditorLocation
Dallas, Texas
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1526 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1526 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
190 usd
CY2023Q4 us-gaap Assets
Assets
1526 usd
CY2022Q4 us-gaap Assets
Assets
190 usd
CY2023Q4 fil Accounts Payable And Accrued Expenses Related Parties
AccountsPayableAndAccruedExpensesRelatedParties
2275 usd
CY2022Q4 fil Accounts Payable And Accrued Expenses Related Parties
AccountsPayableAndAccruedExpensesRelatedParties
2275 usd
CY2023Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
480000 usd
CY2022Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
360000 usd
CY2023Q4 fil Loans Or Advances From Related Party
LoansOrAdvancesFromRelatedParty
98319 usd
CY2022Q4 fil Loans Or Advances From Related Party
LoansOrAdvancesFromRelatedParty
76077 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
12999 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
7695 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
593593 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
446047 usd
CY2023Q4 us-gaap Liabilities
Liabilities
593593 usd
CY2022Q4 us-gaap Liabilities
Liabilities
446047 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5248582 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5248582 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5248 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5248 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5417236 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5417236 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6014551 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5868341 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-592067 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-445857 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1526 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
190 usd
CY2023 us-gaap Revenues
Revenues
0 usd
CY2022 us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
120000 usd
CY2022 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
120000 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20907 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21035 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
140907 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
141035 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-140907 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-141035 usd
CY2023 us-gaap Interest Expense
InterestExpense
5303 usd
CY2022 us-gaap Interest Expense
InterestExpense
4039 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5303 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4039 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-146210 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-145074 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5248582 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5248582 shares
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-445857 usd
CY2023 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-146210 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-592067 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-146210 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-145074 usd
CY2023 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
120000 usd
CY2022 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
120000 usd
CY2023 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
5304 usd
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
4039 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20906 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21035 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
22242 usd
CY2022 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
21000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22242 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21000 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1336 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-35 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
225 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1526 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190 usd
CY2023 us-gaap Interest Paid
InterestPaid
0 usd
CY2022 us-gaap Interest Paid
InterestPaid
0 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt"><b>NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES</b></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">HST Global, Inc. (“the Company”) was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation. The Company has made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a Merger and share exchange agreement with Health Source Technologies, Inc. This business acquisition has been accounted for as a reverse merger or recapitalization of Health Source Technologies, Inc (“Health Source”). At the time of the merger NT Holding Corporation had disposed of its assets and liabilities and had minimal operations. Immediately after the acquisition the Company changed its name to HST Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of the State of Nevada on August 6, 2007. The Company is currently headquartered in Hampton, Virginia.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">The Company is an integrated health and wellness biotechnology company with a plan to develop and/or acquire a network of wellness centers worldwide with the primary focus on homeopathic and alternative treatments of late stage cancer and other life threatening diseases.  In addition, the Company intends to acquire innovative products for the treatment of life threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer and/or life threatening diseases.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">To date we have been unable to initiate our original business plan.  While we are continuing to seek opportunities to do so, we are also seeking other opportunities to integrate assets, rights, or other potential revenue streams. </p>
CY2023 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify"><span style="border-bottom:1px solid #000000">Basis of Presentation</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The accompanying consolidated financial statements and related notes include the activity of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-K.</p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify"><span style="border-bottom:1px solid #000000">Use of Estimates</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
-30704 usd
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
-30466 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
30704 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
30466 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1284447 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1253743 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
113692 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
113692 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1170755 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1140051 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd

Files In Submission

Name View Source Status
0001674796-24-000003-index-headers.html Edgar Link pending
0001674796-24-000003-index.html Edgar Link pending
0001674796-24-000003.txt Edgar Link pending
0001674796-24-000003-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hstc-20231231.htm Edgar Link pending
hstc-20231231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hstc-20231231_cal.xml Edgar Link unprocessable
hstc-20231231_def.xml Edgar Link unprocessable
hstc-20231231_lab.xml Edgar Link unprocessable
hstc-20231231_pre.xml Edgar Link unprocessable
hstc-20231231_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable